Iron
Active ingredient
Sold as VENOFER · VELPHORO · ACCRUFER · FERRLECIT · FERINJECT
- Drug class
- -
- Availability
- Prescription only
- Routes
- Intravenous, Oral
- Markets covered
- 3
- Products on record
- 12
- FDA reports (12 mo)
- 4,457
Overview
Plain-language summary, compiled from the cited regulatory records
Iron is an essential mineral used in the treatment of anemias that respond to oral iron therapy [1]. These anemias can be associated with pregnancy, chronic or acute blood loss, metabolic disease, postsurgical recovery, and dietary deficiencies [1].
Iron is available under various brand names, including IROSPAN 24/6, Ferralet 90, and Davimet with Iron [1]. In the past 12 months, there have been 4,457 adverse event reports associated with iron-containing products [2]. The most frequently reported issues in these reports include off-label use, diarrhea, nausea, fatigue, and dyspnea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 7 | July 10, 2025 |
| US United States | FDA | 3 | January 7, 2026 |
| GB United Kingdom | MHRA | 2 | June 16, 2025 |
CACanada· Health Canada
7 products
Uses
FERINJECT (ferric carboxymaltose) is indicated: • for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective. • for the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.
The diagnosis of iron deficiency must be based on laboratory tests. 1 Pediatrics Pediatrics (1-17 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FERINJECT in pediatric patients has been established.
2 Recommended Dose and Dosage Adjustment). 3 CLINICAL PHARMACOLOGY, Pharmacokinetics). The efficacy and safety of FERINJECT has not been investigated in children below 1 year of age. FERINJECT is therefore not recommended for use in children in this age group.
4 Geriatrics).
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
Ferralet ® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs.
How to take
GBUnited Kingdom· MHRA
2 products
Uses
1. g. in the presence of organic disease such as malignancy and immune deficiency syndromes, such as AIDS. 2. g. malabsorption, inflammatory bowel disease and fistulae, short bowel syndrome and Crohn’s disease, and where concurrent medication decreases vitamin and mineral absorption.
3. g. where anorexia or cachexia exists and following chemo- or radio-therapy. 4. g. where nutritional intake continues to be inadequate. 5. g. in renal diets and where several food groups are restricted in therapeutic weight reducing diets.
6. g. exclusion diets. 7. g. in phenylketonuria, galactosaemia and ketogenic diets.
How to take
Drug interactions
Known interactions involving Iron. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02546078 · revised July 10, 2025
- [2]FDA DailyMed · 0be2918e-55b3-4c… · revised January 7, 2026 [PDF]
- [3]MHRA (UK) · PL168530079 · revised June 16, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.